Skip to content

Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients
Read More…

  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Advisory Board
    • Program Advisors
  • R & D
    • GT103
    • Platform
    • Pipeline
  • Investors & Partnering
  • Patients & Families
  • News
    • Press Releases
    • Publications & Presentations
  • Contact Us

News

Author: Scott Lyman

Grid Therapeutics Closes Series B Financing

Posted on April 26, 2018April 26, 2018, in News, Press Releases
Read more

Grid Therapeutics Selected by the NCI’s NExT Program to Complete the IND Enabling Nonclinical Work for GT103

Posted on October 31, 2017October 31, 2017, in News, Press Releases
Read more

Grid Therapeutics Collaborates with Catalent to Develop the First Human-Derived Antibody for the Treatment of Cancer

Posted on October 31, 2017, in News, Press Releases
Read more

Grid Therapeutics Closes Series A Financing

Posted on September 20, 2017, in News, Press Releases
Read more

Grid Therapeutics Signs Exclusive License to Develop a Novel Immuno-Oncology Antibody

Posted on August 28, 2017, in News, Press Releases
Read more
  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Advisory Board
    • Program Advisors
  • R & D
    • GT103
    • Platform
    • Pipeline
  • Investors & Partnering
  • Patients & Families
  • News
    • Press Releases
    • Publications & Presentations
  • Contact Us
© 2022 Grid Therapeutics. All rights reserved.